Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
11.68 USD | -1.43% | +0.09% | -4.65% |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | 14.95M | Capitalization | 493M |
---|---|---|---|---|---|
Net income 2024 * | -114M | Net income 2025 * | -111M | EV / Sales 2024 * | - |
Net cash position 2024 * | 218M | Net cash position 2025 * | 105M | EV / Sales 2025 * | 26 x |
P/E ratio 2024 * |
-3.84
x | P/E ratio 2025 * |
-4.84
x | Employees | 118 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.77% |
Latest transcript on KalVista Pharmaceuticals, Inc.
1 day | -1.43% | ||
1 week | +0.09% | ||
Current month | +0.09% | ||
1 month | -3.39% | ||
3 months | -18.66% | ||
6 months | +43.14% | ||
Current year | -4.65% |
Managers | Title | Age | Since |
---|---|---|---|
Ed Feener
FOU | Founder | 64 | 04-03-25 |
Ben Palleiko
CEO | Chief Executive Officer | 58 | 16-07-31 |
Paul Audhya
CTO | Chief Tech/Sci/R&D Officer | 51 | 21-05-02 |
Members of the board | Title | Age | Since |
---|---|---|---|
Brian Pereira
CHM | Chairman | 65 | 19-01-31 |
Ben Palleiko
CEO | Chief Executive Officer | 58 | 16-07-31 |
Albert Cha
BRD | Director/Board Member | 51 | 15-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.04% | 2 M€ | -.--% | ||
0.03% | 0 M€ | 0.00% | - | |
0.00% | 9 M€ | +9.52% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-06-07 | 11.68 | -1.43% | 243,242 |
24-06-06 | 11.85 | -1.82% | 104,230 |
24-06-05 | 12.07 | +1.77% | 172,222 |
24-06-04 | 11.86 | -2.06% | 219,519 |
24-06-03 | 12.11 | +3.77% | 548,921 |
Delayed Quote Nasdaq, June 07, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-4.65% | 493M | |
+0.82% | 91.94B | |
-1.32% | 38.74B | |
-12.88% | 32.82B | |
+64.13% | 26.66B | |
-16.31% | 15.32B | |
-11.38% | 11.65B | |
+173.10% | 10.37B | |
-49.84% | 10.12B | |
+3.75% | 9.06B |
- Stock Market
- Equities
- KALV Stock